Search Results - "Soulie, Matthieu"
-
1
Transient heart rate reduction improves acute decompensated heart failure‐induced left ventricular and coronary dysfunction
Published in ESC Heart Failure (01-04-2021)“…Aims Acute decompensated heart failure (ADHF), a live‐threatening complication of heart failure (HF), associates a further decrease of the already by…”
Get full text
Journal Article -
2
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
Published in International journal of molecular sciences (01-02-2023)“…The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications…”
Get full text
Journal Article -
3
Protein Alterations in Cardiac Ischemia/Reperfusion Revealed by Spatial-Omics
Published in International journal of molecular sciences (10-11-2022)“…Myocardial infarction is the most common cause of death worldwide. An understanding of the alterations in protein pathways is needed in order to develop…”
Get full text
Journal Article -
4
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
Published in Journal of the American Heart Association (18-06-2024)“…The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Classic…”
Get full text
Journal Article -
5
Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
Published in Endocrinology, diabetes & metabolism (01-07-2020)“…Introduction Imeglimin, a glucose‐lowering agent targeting mitochondrial bioenergetics, decreases reactive oxygen species (ROS) overproduction and improves…”
Get full text
Journal Article -
6
Abstract 103: Combined Dapagliflozine And Eplerenone Treatment Improve Cardiorenal Function In Rats With Chronic Kidney Disease
Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)“…Abstract only Background: Patients with chronic kidney disease (CKD) present higher risk of cardiovascular (CV) complications as well as renal function…”
Get full text
Journal Article -
7
NGAL is a Novel Target in Hypertension by Modulating the NCC-Mediated Renal Na Balance
Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)“…The expression of NGAL/lcn2 (neutrophil gelatinase-associated lipocalin) is directly modulated by mineralocorticoid receptor activation but its role in blood…”
Get full text
Journal Article -
8
Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease
Published in M.S. Médecine sciences (24-04-2023)“…Diabetic kidney disease (DKD) and its associated cardiovascular morbidity represent a major complication in diabetic patients. Over the past two decades,…”
Get more information
Journal Article -
9
Abstract 080: The Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction In Preclinical Non-diabetic Chronic Kidney Disease
Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)“…Abstract only Background: The mineralocorticoid receptor (MR) plays an important role in the development of Chronic Kidney Disease (CKD) and its overactivation…”
Get full text
Journal Article -
10
386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Introduction: PXL770 is a direct AMP kinase activator. In models of T2DM and NASH, PXL770 improves hyperglycemia and dyslipidemia and reduces: steatosis,…”
Get full text
Journal Article -
11
Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway
Published in Clinical science (1979) (21-08-2024)“…Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists…”
Get more information
Journal Article -
12
-
13
Combined Dapagliflozin and Eplerenone Treatment Improve Cardiorenal Function in Rats with CKD: FR-PO399
Published in Journal of the American Society of Nephrology (01-11-2023)Get full text
Journal Article -
14
Altered ECG parameters with loss of cardiac variability and prolonged QTc in a non-diabetic chronic kidney disease rat model
Published in Archives of cardiovascular diseases (01-06-2024)“…Patients with Chronic Kidney Disease (CKD) have increased risk of cardiovascular mortality from arrhythmias and sudden cardiac death. The pathogenesis by which…”
Get full text
Journal Article -
15
1963-P: Short- and Long-Term Empagliflozin Treatment Improves Cardiac Function in Rats with Chronic Heart Failure
Published in Diabetes (New York, N.Y.) (01-06-2020)“…Introduction: The SGLT2 inhibitor empagliflozin (EMPA) exerts beneficial cardiovascular effects in type-2 diabetes, but whether this occurs in chronic heart…”
Get full text
Journal Article -
16
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
Published in International journal of molecular sciences (28-01-2023)“…The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications…”
Get full text
Journal Article -
17
-
18
Combined dapagliflozine and eplerenone treatment improve cardiorenal function in rats with chronic kidney disease
Published in Archives of cardiovascular diseases (01-06-2024)“…Patients with chronic kidney disease (CKD) present higher risk of cardiovascular (CV) complications as well as renal function decline. The DAPA-CKD trial…”
Get full text
Journal Article -
19
-
20
Cover Image
Published in Endocrinology, diabetes & metabolism (22-07-2020)“…Cover caption The cover image is based on the Original Article “ Short‐ And Long‐Term Administration of Imeglimin Counters Cardiorenal Dysfunction in a Rat…”
Get full text
Journal Article